Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Real-time Quote. Real-time Tradegate - 02/09 12:50:36 pm
68.613 EUR   -1.86%
10:49a SANOFI : and Positive Planet Partnership Promote Access to Care and ..
08:07a SANOFI : Delivered 2015 Business EPS up 8.5% on a Reported Basis and..
07:56aDJRegeneron Reports Slowing Sales Growth for Key Eye Drug
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

02/22/2013 | 07:58am US/Eastern

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
React to this article
Latest news on SANOFI
10:49a SANOFI : and Positive Planet Partnership Promote Access to Care and Quality of H..
08:07a SANOFI : Delivered 2015 Business EPS up 8.5% on a Reported Basis and Stable at C..
07:56aDJRegeneron Reports Slowing Sales Growth for Key Eye Drug
04:45a Sanofi pledges stable 2016 earnings
04:33a SANOFI : reports flat 2015 earnings
04:24a Sanofi pledges stable 2016 earnings
03:56aDJSanofi Profit Hit By Falling Diabetes Revenue -- Update
03:26aDJSanofi Profit Hit By Falling Diabetes Revenue
02:14a SANOFI : Full Year 2015 Results
01:46aDJSanofi Profit Hit By Falling Diabetes Revenue
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials